Displaying 1 - 12 of 35
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Bayer: Addressing a Changing Treatment Dynamic in HCC:  Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Liver Tumours
5

Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Displaying 1 - 12 of 35